Amarin Corp. (AMRN) Announces Presentation of Positive Pure EPA Vascepa Data
- Consumer staples stocks help Wall St. pare some losses
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Verizon Communications (VZ) May Acquire Big Cable Company - NYP (CHTR) (CMCSA)
- Citron Research Negative on Lannett (LCI); Sees Shares at 'Zero' Over Long Term
- Einhorn's Greenlight Mentions Caterpillar (CAT) Short in Q4 Letter; Doesn't See Disney (DIS) Buying Netflix (NFLX)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Amarin Corporation plc (Nasdaq: AMRN) announced an oral presentation at the American Heart Association Scientific Sessions 2016, New Orleans on November 14, 2016 that further characterized the efficacy and safety of Vascepa (icosapent ethyl) in statin-treated women with persistent high triglyceride levels.
The presentation of additional data from the ANCHOR study showed, consistent with overall study results, that prescription pure EPA Vascepa® (icosapent ethyl) reduced triglyceride levels and several other potentially atherogenic lipid parameters and inflammatory markers in a subgroup of statin-treated women with persistent high triglycerides. The post hoc analysis supporting the efficacy of pure, prescription icosapent ethyl in this patient population was presented as an oral abstract (#309) titled, “Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Statin-Treated Women With Persistent High Triglycerides: Results From the ANCHOR Study.”
The analysis is published in the American Journal of Cardiology; an early version of the manuscript is accessible at http://www.ajconline.org/article/S0002-9149(16)31738-6/pdf.
The analysis was led by Lori Mosca, MD, MPH, PhD, Professor of Medicine Emerita and Center Director of the American Heart Association Go Red for Women Research Network at Columbia University Medical Center, New York. Researchers observed that compared to placebo, Vascepa administered at 4 g/day significantly reduced triglycerides (TGs) without increasing LDL (“bad”) cholesterol in women from the ANCHOR study with TG levels between 200 to 499 mg/dL. In addition, statistically significant improvements were observed in numerous potentially atherogenic parameters (lipids and lipoproteins) and inflammatory markers.
"It is important to generate data that address the specific needs of women, especially in fields where the data could prove useful to patient care," said Dr. Mosca. “While further study is needed and ongoing, this analysis is encouraging because the efficacy and safety of Vascepa 4 g/day in this subgroup of 91 statin-treated women with persistent high triglycerides were consistent with the overall ANCHOR results, which included 702 patients. It is vitally important to evaluate both potential benefits and side effects of therapies in women and not assume results from men are similar in women."
The clinical implications of lowering triglycerides with Vascepa 4 g/day are being investigated in the REDUCE-IT cardiovascular outcomes study of statin-treated women and men with persistent elevated TG levels.
The ANCHOR study and post hoc analysis were sponsored by Amarin and were not affiliated with or funded by the American Heart Association (AHA) or the AHA Go Red for Women Research Network.
About the Presented Research
Dr. Mosca’s analysis was based on a post hoc subgroup analysis of 179 women in the ANCHOR trial, a study that investigated Vascepa as a treatment for patients with residual high TG (≥200 and <500mg/dL) despite statin-induced control of LDL-C. ANCHOR enrolled 702 patients, of which the majority (73%) had Type 2 diabetes. The primary endpoint was percent change in TG levels from baseline to 12 weeks compared with placebo in subjects treated with placebo or Vascepa at 2 or 4 g/day. In April 2011, Amarin reported top-line results from the ANCHOR trial, which met its primary and secondary endpoints.
The subgroup analysis presented at the American Heart Association Scientific Sessions 2016 evaluated the efficacy of Vascepa on TG levels, potentially atherogenic (lipid and lipoprotein) parameters and inflammatory markers among a subgroup of women (97% white, 82% with diabetes, mean age 62 years) that were randomized to receive either Vascepa 4 g/day (n=91) or placebo (n=88) from baseline to week 12.
The analysis showed that, compared to placebo, Vascepa significantly reduced TGs (−22%; P<0.0001) without increasing LDL-C (-6%; P>0.05). Significant improvement in other potentially atherogenic parameters (non-HDL-C, VLDL-C, VLDL-TG, apoB, RLP-C) and inflammatory markers (Ox-LDL, Lp-PLA2, hsCRP) were also observed vs. placebo (P<0.05 for all).
As with many subgroup analyses, a limitation is the small sample size, but the results are nonetheless suggestive of complementary beneficial changes in TG levels and other potentially atherogenic parameters and inflammatory markers as compared with placebo. The efficacy and safety of Vascepa 4 g/day in women were consistent with the overall ANCHOR results.
Amarin's clinical development program for Vascepa includes a trial known as REDUCE-IT. REDUCE-IT is a global Phase 3, randomized, multicenter, double-blind, placebo-controlled study designed to evaluate whether treatment with Vascepa reduces cardiovascular events in patients who despite stabilized statin therapy have elevated triglyceride levels and other cardiovascular risk factors. The primary endpoint of the study is the time to the first occurrence of the composite endpoint of cardiovascular death, nonfatal myocardial infarction (heart attack), nonfatal stroke, coronary revascularization, or hospitalization for unstable angina. Secondary endpoints include time to event analyses of components of the primary endpoint. The study is being conducted under a special protocol assessment agreement with the FDA.
Additional information on ANCHOR, REDUCE-IT and Amarin's other clinical studies of Vascepa can be found at www.clinicaltrials.gov.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB), Forward Pharma (FWP) Enter Settlement and License Agreement; Biogen to Pay $1.25B, Royalties
- Concert Pharma (CNCE) Initiates Placebo-Controlled Phase 2 of CTP-656 in CF in U.S.; Plans Open-Label Phase 2 in EU in Q2
- Materion Corp. (MTRN) Announces Two Patents for Fabrication Process of BrushForm 158
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!